Skip to main content Accessibility help
  • Print publication year: 2014
  • Online publication date: April 2014

Chapter 3 - Principles of management in movement disorders

from Section I - General principles



Over the past few decades neurology has become a field not only of refined and ever-more precise diagnostics, but has also seen a tremendous growth of its therapeutic armentarium. Movement disorders are a paradigmatic example of this development, with Parkinson’s disease being the first neurodegenerative disease – and still the only one – for which pharmacological substitution of an underlying neurotransmitter defect is able to largely abolish symptoms in the majority of patients for extended periods of time. Effective drug therapies are also available for a variety of other movement disorders, including tremor, chorea, dystonia, tics, or myoclonus. Management of movement disorders, however, goes far beyond medical therapy and includes non-pharmacological measures such as exercise and physical therapies, retraining programmes, biofeedback strategies, as well as occupational and speech therapies. More recently, local chemodenervation of selected muscles using targeted botulinum toxin injections has provided a highly successful new treatment modality for a variety of hyperkinetic focal disorders. Furthermore, functional stereotactic neurosurgery can provide dramatic benefit even in instances of severely disabling drug refractory movement disorder conditions including Parkinson’s disease, essential tremor disorders, and dystonia.

Most, if not all, evidence for efficacy of these different approaches has come from clinical trials in selected, homogeneous populations of subjects with degenerative or idiopathic varieties of the different movement disorder syndromes. There is much less formal evidence to guide treatment decisions in those patients in whom movement disorders appear in the context of systemic diseases or as part of the symptomatic spectrum of general neurological conditions. Managing patients with these types of disorders is, of course, first guided by treatment and – if possible – cure of the underlying condition. In many instances this will not be possible or movement disorders may persist as a sequel of the primary condition. Secondly, symptomatic therapies of the movement disorders must be built on correct phenomenology and classification of the type of movement disorder present or identification of the most relevant disturbance in the setting of mixed movement disorders. Selected treatments will then frequently be those that have been shown to be effective in idiopathic varieties of the same disorder. Thirdly, the management approach will often have to be multimodal, combining non-pharmacological, pharmacological and, less often, neurosurgical approaches, and multidisciplinary, involving not only the primary care physician and a neurologist, but also allied health professionals, including specially trained nurses, psychologists, and physical, occupational, and speech therapists.

Related content

Powered by UNSILO
Baizabal-Carvallo, J. F. and Jankovic, J. (2012). “Movement disorders in autoimmune diseases,” Mov. Disord. 27(8): 935–46.
Baizabal-Carvallo, J. F. S., Muscal, E., and Jankovic, J. (2013). “The spectrum of movement disorders in children with anti-NMDA receptor encephalitis,” Mov. Disord. (in press).
Ballard, P. A., Tetrud, J. W., and Langston, J. W. (1985). “Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases,” Neurology 35(7): 949–56.
Cardoso, F. (2008). “Chorea” in Hallett, M. and Poewe, W. (eds.), Therapeutics of Parkinson’s Disease and Other Movement Disorders (Oxford: Wiley-Blackwell), pp. 317–30.
Chatterjee, A., Louis, E. D., and Frucht, S. (2002). “Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis,” Mov. Disord. 17(3): 614–15.
D’Amelio, M., Callari, G., Gammino, M., Saia, V., Lupo, I., Salemi, G., et al. (2005). “Levetiracetam in the treatment of vascular chorea: a case report,” European Journal of Clinical Pharmacology 60(11): 835–6.
Deuschl, G. (2008). “Other tremor disorders” in Hallett, M. and Poewe, W. (eds.), Therapeutics of Parkinson’s Disease and Other Movement Disorders, 1st edn. (Oxford: Wiley-Blackwell).
Deuschl, G., Raethjen, J., Hellriegel, H., and Elble, R. (2011). “Treatment of patients with essential tremor,” Lancet Neurol. 10(2): 148–61.
Edwards, T. C., Zrinzo, L., Limousin, P., and Foltynie, T. (2012). “Deep brain stimulation in the treatment of chorea,” Mov. Disord. 27(3): 357–63.
Fahn, S. (2002). “Overview, history, and classification of myoclonus,” Advances in Neurology 89: 13–17.
Gatto, E. M., Uribe Roca, C., Raina, G., Gorja, M., Folgar, S., and Micheli, F. E. (2004). “Vascular hemichorea/hemiballism and topiramate,” Mov. Disord. 19(7): 836–8.
Hu, S. C. and Shibasaki, H. (2008). “Myoclonus” in Hallett, M. and Poewe, W. (eds.), Therapeutics of Parkinson’s Disease and Other Movement Disorders, 1st edn. (Oxford: Wiley-Blackwell), pp. 363–70.
Huang, Y. G., Chen, Y. C., Du, F., Li, R., Xu, G. L., Jiang, W., et al. (2005). “Topiramate therapy for paroxysmal kinesigenic choreoathetosis,” Mov. Disord. 20(1): 75–7.
Hughes, A.J., Daniel, S.E., Kilford, L., and Lees, A.J. (1992). “Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases,” J. Neurol. Neurosurg. Psychiatry 55(3): 181–4.
Jankovic, J. (2009). “Treatment of hyperkinetic movement disorders,” Lancet Neurol. 8(9): 844–56.
Jankovic, J. and Clarence-Smith, K. (2011). “Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders,” Expert Review of Neurotherapeutics 11(11): 1509–23.
Jankovic, J. and Poewe, W. (2012). “Therapies in Parkinson’s disease,” Current Opinion in Neurology 25(4): 433–47.
Kalia, L. V., Brotchie, J. M., and Fox, S. H. (2013). “Novel nondopaminergic targets for motor features of Parkinson’s disease: Review of recent trials,” Mov. Disord. 28(2): 131–44.
Katzenschlager, R., Manson, A. J., Evans, A., Watt, H., and Lees, A.J. (2004). “Low dose quetiapine for drug induced dyskinesias in Parkinson’s disease: a double blind cross over study,” J. Neurol. Neurosurg. Psychiatry 75(2): 295–7.
Kenney, C., Hunter, C., and Jankovic, J. (2007). “Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders,” Mov. Disord. 22(2): 193–7.
Keswani, S. C., Kossoff, E. H., Krauss, G. L., and Hagerty, C. (2002). “Amelioration of spinal myoclonus with levetiracetam,” J. Neurol. Neurosurg. Psychiatry 73(4): 457–8.
Mehta, S. H., Morgan, J. C., and Sethi, K. D. (2009). “Paroxysmal dyskinesias,” Current Treatment Options in Neurology 11(3): 170–8.
Nath, A., Hobson, D.E., and Russell, A. (1993). “Movement disorders with cerebral toxoplasmosis and AIDS,” Mov. Disord. 8(1): 107–12.
Shibasaki, H. (2006). “Neurophysiological classification of myoclonus,” Neurophysiologie Clinique (Clinical Neurophysiology) 36(5–6): 267–9.
Shin, H. W. and Chung, S. J. (2012). “Drug-induced parkinsonism,” J. Clin. Neurol. 8(1): 15–21.
Siniscalchi, A., Gallelli, L., Davoli, A., and De Sarro, G. (2007). “Efficacy and tolerability of topiramate in vascular generalized chorea,” Annals of Pharmacotherapy 41(11): 1915.
Siniscalchi, A., Mancuso, F., Russo, E., Ibbadu, G. F., and De Sarro, G. (2004). “Spinal myoclonus responsive to topiramate,” Mov. Disord. 19(11): 1380–1.
Striano, P., Coppola, A., Vacca, G., Zara, F., Brescia Morra, V., Orefice, G., et al. (2006). “Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study,” J. Neurol. 253(6): 762–6.
Strzelczyk, A., Burk, K., and Oertel, W. H. (2011). “Treatment of paroxysmal dyskinesias,” Expert Opinion on Pharmacotherapy 12(1): 63–72.
Yaltho, T. C. and Jankovic, J. (2011). “The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms,” Mov. Disord. 26(9): 1582–92.
Zesiewicz, T. A., Pathak, A., Sullivan, K. L., Shamayev, M., and Hauser, R. A. (2006). “Treatment of chorea with levetiracetam,” European Journal of Clinical Pharmacology 62(1): 87.